MAP™ is investigational. Tempo's lead product has been submitted to the FDA through the De Novo pathway and has not been cleared.
Research reported on this site is supported in part by the National Cancer Institute of the National Institutes of Health under Award Number R44CA314892. The content is solely the responsibility of Tempo Therapeutics and does not necessarily represent the official views of the National Institutes of Health. Financial Conflicts of Interest statement
© 2026 Tempo Therapeutics, Inc. All rights reserved.